Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

Homepage | Forums | Main Forums | Universal Healthcare / Medicare For All | Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply

Viewing 0 reply threads
  • Author
    Posts
    • #430360
      eridani
      Participant
      • Total Posts: 9,978

      https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2020.00896?journalCode=hlthaff

      Medicare Part D spending for ultra-expensive brand-name drugs, 2018:
      —122 – Total number of drugs
      —278,000 – Total number of beneficiaries
      —$24,550,000,000 – Total spending
      —$175,513 – Average spending per beneficiary per drug

      (The table also includes a section for drugs that are only expensive, defined as those that were not ultra-expensive but whose annual per beneficiary total spending was more than the yearly average Social Security benefits of retired workers [$16,848 in 2018]. These expensive drugs were consumed by 651,000 beneficiaries at an average of $34,451 per drug for total Medicare Part D spending of $21,552,000,000.)

      The number of ultra-expensive drugs covered by Medicare Part D increased from 23 in 2012 to 122 in 2018.

      We note that sixty-one drugs (50 percent of ultra-expensive drugs in 2018) entered the market as ultra-expensive drugs between 2012 and 2018; 31 percent were on the market but not ultra-expensive in 2012 and became ultra-expensive by 2018.

      Comment by Don McCanne of PNHP:  Drug spending is out of control and getting much worse. By the standards in the article, the newly released, likely-ineffective Alzheimer’s drug, aducanumab, at $56,000 per year, is considered onl expensive and not ultra-expensive.

      Imagine, single drug pricing per beneficiary in excess of the per capita GDP. Wasn’t the equivalent of taking a full year’s Social Security retiree benefits for a single drug enough?

      Perhaps the most important statement in this article, which is decidedly an understatement, is that “policy makers should pay attention to this drug category.”

      Perhaps we should approach Sen. Joe Manchin, as a moderate conservative, and explain the situation to him so he can lead a unified Congress to do something about it. But, wait a minute, wasn’t it his daughter, Heather Bresch, as CEO of Mylan, who purchased the company, Abbott, that sold the EpiPen brand of epinephrine, and then increased its price by 461 percent?

      Sadly, this Congress has already shown its lack of concern by its inaction; this price gouging is taking place under its very nose. No, we need to elect a Congress that will not only pay attention, but one that will actually do something about it. We certainly can no longer leave it up to the pharmaceutical industry to come up with fair pricing for its products.

      Jesus: Hey, Dad? God: Yes, Son? Jesus: Western civilization followed me home. Can I keep it? God: Certainly not! And put it down this minute--you don't know where it's been! Tom Robbins in Another Roadside Attraction

Viewing 0 reply threads
  • You must be logged in to reply to this topic.